UK markets close in 5 hours 42 minutes

AgeX Therapeutics, Inc. (AGE)

NYSE American - NYSE American Delayed price. Currency in USD
Add to watchlist
0.7000+0.0200 (+2.94%)
At close: 01:51PM EDT
0.7060 +0.01 (+0.86%)
After hours: 07:31PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 26.56M
Enterprise value 36.98M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)758.78
Price/book (mrq)12.96
Enterprise value/revenue 1.06k
Enterprise value/EBITDA -4.78

Trading information

Stock price history

Beta (5Y monthly) 1.52
52-week change 3-44.00%
S&P500 52-week change 3-5.62%
52-week high 31.3900
52-week low 30.5160
50-day moving average 30.6819
200-day moving average 30.7579

Share statistics

Avg vol (3-month) 328.57k
Avg vol (10-day) 319.92k
Shares outstanding 537.94M
Implied shares outstanding 6N/A
Float 818.45M
% held by insiders 143.48%
% held by institutions 117.66%
Shares short (14 Jul 2022) 4315.83k
Short ratio (14 Jul 2022) 411.2
Short % of float (14 Jul 2022) 41.47%
Short % of shares outstanding (14 Jul 2022) 40.83%
Shares short (prior month 14 Jun 2022) 4324.42k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Mar 2022

Profitability

Profit margin 0.00%
Operating margin (ttm)-8,384.95%

Management effectiveness

Return on assets (ttm)-165.89%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)93k
Revenue per share (ttm)0.00
Quarterly revenue growth (yoy)-91.10%
Gross profit (ttm)125k
EBITDA -7.67M
Net income avi to common (ttm)-9.29M
Diluted EPS (ttm)-0.2450
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)448k
Total cash per share (mrq)0.01
Total debt (mrq)10.87M
Total debt/equity (mrq)N/A
Current ratio (mrq)0.18
Book value per share (mrq)-0.30

Cash flow statement

Operating cash flow (ttm)-6.86M
Levered free cash flow (ttm)-1.69M